ClinicalTrials.gg
RecruitingNCT06978439Updated Oct 22, 2026

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

A Phase 4 interventional study of Rivaroxaban (Xarelto) in Kawasaki Disease, Pilot Study and Coronary Artery Aneurysm, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Children's Hospital of Fudan University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2024, registered May 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University — 5 open to participants now, 5 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · Children's Hospital of Fudan University.

Started
2024
the only one that year
Phase 4
2 of 11
2 open now
Registered
8th of 11
by date

Among the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, this one is the only one that started in 2024, is one of 2 in phase 4, and was the 8th registered.

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

Browse Mucocutaneous Lymph Node Syndrome studies →

Open to participants now

5 of the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, or all of them as a file.
02

Study summary

Based on a population pharmacokinetic model-based dose optimization study, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after Kawasaki disease was proposed. This single-center, single-arm, pilot study aims to evaluate the feasibility of the 15 mg-equivalent dosing regimen within a limited sample size.

Patients will be followed for more than 6 months. Clinical outcomes, including coronary artery thrombosis, major adverse cardiovascular events, and bleeding events, will be recorded. Rivaroxaban levels will be measured to assess the robustness of the model-informed dose optimization.

Read the detailed description

Giant coronary artery aneurysm (GCAA) is a rare but severe cardiac complication of Kawasaki disease (KD). Due to the abnormal blood rheology and the hyper-inflammatory response accompanied by thrombocytosis during the acute phase, patients with GCAA are at high risk of coronary artery thrombosis and major adverse cardiovascular events.In such instances, lifelong antiplatelet (aspirin or clopidogrel) and anticoagulant therapy (warfarin or low molecular weight heparin, LMWH) may become necessary.

In 2022, two compounds, the direct activated Factor X (FXa) inhibitor rivaroxaban was approved by international regulatory agencies for two specific pediatric indications, supported by pharmacometrics models. For instance, a dosing regimen matching exposures of 20 mg daily in adults (the 20 mg-equivalent dosing regimen) is indicated for children under 18 years with venous thromboembolism (VTE). Secondly, a dosing regimen matching exposures of 10 mg daily in adults (the 10 mg-equivalent dosing regimen) is indicated for post-Fontan patients aged two years or older, as shown in the UNIVERSE study, which compared rivaroxaban to aspirin. However, no trials have yet compared rivaroxaban with warfarin/LMWH in pediatric patients with GCAA after KD.

Inter-ethnic population pharmacokinetic (PPK) analyses have suggested that Asian patients may require a lower dosage of rivaroxaban, consistent with the findings from the J-ROCKET trail in Japanese adults. Accordingly, the maximum dosage for Japanese children with VTE (≥ 50 kg) has reduced from 20 mg q24h (every 24 hours) to 15 mg q24h. However, reports on rivaroxaban use in pediatric patients with GCAA after KD, especially in those from Asian countries, remains limited. Its application is more challenging due to (i) increased bleeding risk from concomitant antiplatelet drug use; (ii) the predominance of younger patients (typically \< 3 years) with variability in hepatic and renal function, as well as growth and development.3 Given the low incidence of GCAA, quantitative pharmacometrics is a highly promising approach for precision dosing of rivaroxaban in these patients.

Therefore, the investigators retrospectively collected the clinical experience of rivaroxaban off-label use in Chinese pediatric patients with GCAA after KD from 2023.1 to 2023.12. With clinical evidence and model-extrapolation, the investigators conducted a quantitative pharmacometrics model-based dose optimization study and proposed a 15 mg-equivalent dosing regimen for thromboprophylaxis in Chinese children with GCAA after KD, those who require dual antithrombotic therapy.

This pilot study aims to assess the potential of rivaroxaban for thromboprophylaxis in pediatric patients with KD after GCAA. Specifically, this study seeks to: (ⅰ) preliminarily evaluate the feasibility, efficacy and safety of the 15 mg-equivalent dosing regimen in target population, (ii) provide pharmacokinetic (PK)/pharmacodynamic (PD) data on rivaroxaban in Chinese children.

03

Conditions studied

  • Kawasaki Disease
  • Pilot Study
  • Coronary Artery Aneurysm
  • Rivaroxaban

Keywords

  • kawasaki disease
  • giant coronary artery aneurysm
  • rivaroxaban
  • model-informed dose optimization
  • anticoagulant
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≥10 or coronary artery internal diameter ≥8mm;
  2. Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 6 months;
  3. Participant should be able to tolerate oral feeding, nasogastric or gastric feeding;
  4. Children aged 1 Month to\<18 years, bodyweight ≥ 2600g.

Exclusion criteria

Exclusion Criteria:

  1. Active bleeding or bleeding risk contraindicating anticoagulant therapy
  2. With history of venous thromboembolism or risk factors related with venous thromboembolism, like congenital heart disease, carcinoma, central venous catheter or long-term immobilization.
  3. or any other listed in the local labeling for the comparator treatment or experimental treatment
  4. An \<30 mL/min/1.73 m2 (For children younger than 1 year, serum creatinine results above 97.5th percentile)
  5. count \< 100 x 109/L
  6. Hepatic disease which is associated with either: coagulopathy leading to a bleeding risk, or > 5x or total > 2x ULN with direct bilirubin > 20% of the total
  7. Sustained uncontrolled hypertension defined as systolic and/or diastolic blood pressure >95 th age percentile
  8. Concomitant use of strong inhibitors of both and P-glycoprotein, including but not limited to all protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed)
  9. Concomitant use of strong inducers of CYP3A4, including but not limited to rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
  10. Hypersensitivity or any other contraindications listed in the local labeling for the comparator treatment or experimental treatment
  11. Inability to cooperate with the study procedures and follow-up visits
  12. Refuse to provide

eGFR, estimated glomerular filtration rate; ULN, upper level of normal; TB, total bilirubin (TB); CYP3A4, cytochrome P450 isoenzyme 3A4

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Rivaroxaban

    Rivaroxaban as anticoagulant will be administered for children with giant coronary artery aneurysm after Kawasaki disease. The initial dosing regimen of rivaroxaban is a 15 mg-equivalent, age and bodyweight-adjusted dosing regimen, which was proposed by the model-informed dose optimization study.

    Drug: Rivaroxaban (Xarelto)

Interventions

  • DrugRivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model-informed dose optimization study

    Also known as: Anticoagulation

06

What researchers measure

Primary outcomes

  1. Occurrence of new thrombosis in coronary arteries

    It is a binary variable. Every echocardiography conducted during study period will be assessed and documented. Investigators will evaluate whether new thrombosis occurs in coronary arteries.

    Time frame: From enrollment to the 6th month after treatment

  2. Composite of Major bleeding or Clinically relevant non-major bleeding event

    It is a binary variable. Major bleeding is defined as 1.Fatal bleeding; 2.Clinically overt bleeding associated with a decrease in Hgb of ≥20 g/L (2 g/dL) in a 24-h period; 3.Critical site bleeding, such as retroperitoneal, pulmonary, pericardial, intracranial, or otherwise involves the central nervous system; 4.Bleeding that requires an intervention via an invasive procedure; 5.Overt bleeding for which a reversal agent is administered. Clinically relevant non-major bleeding event is defined as 1.Bleeding that results in a medical or procedural intervention not meeting major bleeding criteria, including a medication change (reducing, holding, or changing anticoagulation or addition of new medication) ; 2.Bleeding that results in hospitalization or increased level of care; 3.Overt bleeding for which a blood product is administered, and does not meet the criteria for major bleeding

    Time frame: From enrollment to the 6th month after treatment

Secondary outcomes

  1. Occurrence of major adverse cardiovascular event

    It is a binary variable. Major adverse cardiovascular event (MACE) includes unstable angina, acute myocardial infarction, stroke, hospitalization for heart failure, unplanned revascularization, cardiovascular death. If any of the MACEs occur during the study period, it will be recorded as 1; otherwise, it will be recorded as 0. The definition of each MACE refers to the following guidelines and consensus: 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, 2019 European Society of Cardiology Guidelines for the diagnosis and management of chronic coronary syndromes, Fourth universal definition of myocardial infarction, and 2023 European Society of Cardiology Guidelines for the management of acute coronary syndromes.

    Time frame: From enrollment to the 6th month after treatment

  2. Any adverse events

    It is a text variable. If any adverse events( including durg allergy, severe infection, hepatic dysfunction, renal dysfunction, hypertension, fatigue, abdominal pain or others) occur will be reported to the data and safety monitoring board. The detail of adverse event will be recorded, including classification of adverse event, time of occurrence, symptoms, treatment, resolution time, and outcome.

    Time frame: From enrollment to the 6th month after treatment

  3. Any dose adjustments for rivaroxaban

    It is a text variable. Any dose adjustments for rivaroxaban will be recorded, including time of dose adjustment, reason for dose adjustment, dosage, and outcome. Rivaroxaban plasma concentration and rivaroxaban-calibrated anti-factor Xa activity will be measured after at least 3 consecutive doses

    Time frame: From enrollment to the 6th month after treatment

Other outcomes

  1. Plasma concentration of rivaroxaban at specific timepoint

    Rivaroxaban plasma concentration will be measured by high performance liquid chromatography tandem mass spectrometer at specific timepoint. It includes 1. 20 minutes to 1 hour after the first dose; 2. 7 ± 1 hours after the first dose; 3. Ctrough: before the scheduled dose after at least three consecutive doses; 4. Cmax: 3 ± 1 hours after at least three consecutive doses. And Ctrough and Cmax will be re-measured after each dose adjustment.

    Time frame: From enrollment to the 6th month after treatment

  2. Rivaroxaban-calibrated anti-factor Xa activity at specific timepoint

    Rivaroxaban-calibrated anti-factor Xa activity will be measured at specific timepoint. It includes 1. 20 minutes to 1 hour after the first dose; 2. 7 ± 1 hours after the first dose; 3. Ctrough: before the scheduled dose after at least three consecutive doses; 4. Cmax: 3 ± 1 hours after at least three consecutive doses. And Ctrough and Cmax will be re-measured after each dose adjustment.

    Time frame: From enrollment to the 6th month after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
May 18, 2025
StartActual
Jan 10, 2024
Primary completionEst.
Dec 31, 2027was Dec 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2027
Oct 22, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Dec 31, 2025→Dec 31, 2027
    Study completion Dec 31, 2025→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06978439
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Jan 10, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Fang Liu, MD
Contact
liufang@fudan.edu.cn
18017590880
Guangan Dai, MD
Contact
gadai24@m.fudan.edu.cn
13580762996
Fang Liu, MD
study director · Children's Hospital of Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion